Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia), By End Use (Hospitals, Clinics, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 7.88 Billion
CAGR (2026-2031)	6.15%
Fastest Growing Segment	Non-steroidal anti-inflammatory drugs (NSAID)
Largest Market	North America
Market Size (2031)	USD 11.27 Billion

Market Overview

The Global Ankylosing Spondylitis Therapeutics Market will grow from USD 7.88 Billion in 2025 to USD 11.27 Billion by 2031 at a 6.15% CAGR. Ankylosing Spondylitis therapeutics encompass a range of pharmaceutical interventions, including nonsteroidal anti-inflammatory drugs, biologics such as tumor necrosis factor inhibitors and interleukin inhibitors, and Janus kinase inhibitors designed to reduce inflammation and prevent spinal fusion. The primary drivers propelling market growth include the rising global prevalence of autoimmune disorders and an expanding geriatric population that is increasingly susceptible to chronic inflammatory conditions. Furthermore, improved diagnostic capabilities and heightened awareness among healthcare professionals are facilitating earlier detection and intervention, thereby broadening the patient pool eligible for advanced pharmacotherapy.

A significant impediment to market expansion is the substantial economic burden associated with biologic therapies, which limits patient access and strains healthcare reimbursement systems globally. The presence of refractory disease also complicates treatment landscapes. According to the European Alliance of Associations for Rheumatology, in 2025, data presented from the German Rabbit register indicated that approximately 8.5% of patients with axial spondyloarthritis were classified as difficult to manage despite receiving standard care. This statistic underscores the persistent clinical challenge of addressing the needs of patients who do not respond adequately to existing therapeutic options.

Key Market Drivers

The increasing adoption of biologics and targeted therapies serves as a primary catalyst for market progression. Advanced pharmacotherapies, including Janus kinase inhibitors, offer superior efficacy for patients unresponsive to conventional nonsteroidal anti-inflammatory drugs. Major pharmaceutical entities are witnessing substantial revenue growth from these specialized portfolios as clinical preference shifts toward options that modify disease activity rather than merely addressing symptoms. According to AbbVie, October 2024, in the 'Third-Quarter 2024 Financial Results', global net revenues for Rinvoq reached 1.61 billion dollars, representing a reported increase of 45.3 percent compared to the previous year, driven significantly by indications including ankylosing spondylitis. This surge underscores the growing reliance on targeted oral therapies to manage chronic inflammation.

A robust clinical pipeline and the subsequent approval of novel therapeutic agents further accelerate market dynamics. Innovation is moving beyond tumor necrosis factor inhibitors toward dual-action cytokines that target specific inflammatory pathways with greater precision, evidenced by the rapid commercial uptake of recently approved treatments. According to UCB, July 2024, in the '2024 Half-Year Financial Report', net sales for the newly launched bimekizumab amounted to 215 million Euros, highlighting the immediate market impact of next-generation biologics. Additionally, established therapies continue to expand their reach; according to Novartis, in 2024, sales for the interleukin inhibitor Cosentyx grew by 28 percent in constant currencies during the third quarter, confirming sustained demand within the immunology segment.

Download Free Sample Report

Key Market Challenges

The substantial economic burden associated with the management of ankylosing spondylitis acts as a critical barrier to the expansion of the therapeutics market. High-cost biologic interventions place immense pressure on healthcare reimbursement systems, leading to restrictive coverage policies and limited patient access to premium treatments. This financial strain is exacerbated by the broader costs of care and productivity losses, which deplete resources available for advanced pharmacotherapy. According to the Canadian Spondyloarthritis Association, in 2025, the annual economic cost attributed to axial spondyloarthritis was estimated to be $2.01 billion, underscoring the severe financial implications of the condition on health systems. Confronted with such escalated expenditures, payers and insurance providers frequently prioritize cost-containment measures over the adoption of novel, expensive therapies. These economic constraints directly reduce the addressable patient population for high-value drugs and decelerate market revenue growth, preventing the sector from realizing its full commercial potential despite the clinical availability of effective treatments.

Key Market Trends

The Proliferation of Cost-Effective Biosimilars is fundamentally reshaping the market by providing financially viable alternatives to premium-priced reference biologics. As exclusivity periods for major tumor necrosis factor inhibitors conclude, healthcare systems and payers are aggressively prioritizing these lower-cost options to mitigate the escalating budget impact of chronic autoimmune care. This strategic pivot is driving rapid commercial uptake and expanding patient access to biologic therapies previously restricted by cost barriers. According to Sandoz, March 2025, in the 'Sandoz Financial Report 2024', net sales of biosimilars reached $2.9 billion, an increase of 30 percent in constant currencies versus the prior year, reflecting the strong demand for cost-efficient therapies like Hyrimoz in key markets.

The Integration of AI-Driven Diagnostic and Development Tools is concurrently revolutionizing the speed and precision with which new ankylosing spondylitis therapeutics are identified. Pharmaceutical entities are increasingly capitalizing on artificial intelligence to decipher complex inflammatory pathways and optimize lead candidate selection, thereby shortening the traditionally lengthy drug discovery phase. This operational shift is characterized by substantial investments in AI-native biotechnology partnerships aimed at uncovering novel targets for autoimmune conditions. According to BioWorld, January 2026, in the article 'AI drug discovery brings $2B+ Sanofi deal to 1-year-old Earendil', Sanofi secured a partnership worth a potential $2.56 billion to utilize an AI-driven discovery platform for finding new therapeutics for autoimmune and inflammatory diseases.

Segmental Insights

The Non-steroidal anti-inflammatory drugs (NSAID) segment is emerging as the fastest growing category within the Global Ankylosing Spondylitis Therapeutics Market. This rapid expansion is primarily driven by their universal designation as the first-line pharmacologic treatment recommended by authoritative institutions, such as the American College of Rheumatology, for managing active disease. As enhanced diagnostic capabilities globally lead to earlier detection, a rising volume of patients requires immediate intervention. NSAIDs fulfill this critical demand through their cost-effectiveness and widespread accessibility, ensuring their adoption rates outpace those of escalated biologic therapies.

Regional Insights

North America holds a dominant position in the global Ankylosing Spondylitis therapeutics market, driven by a highly developed healthcare infrastructure and rising disease prevalence. The region benefits from substantial investments in drug development and the presence of major pharmaceutical manufacturers. Additionally, favorable regulatory frameworks established by the U.S. Food and Drug Administration encourage the introduction of novel biologics and biosimilars. This market leadership is further supported by comprehensive reimbursement policies and increasing patient awareness, which collectively ensure widespread access to necessary therapeutic interventions across the United States and Canada.

Recent Developments

• In August 2025, Akeso Inc. reported positive topline results from a Phase 3 clinical trial of gumokimab (AK111), a novel monoclonal antibody targeting interleukin-17A (IL-17A), for the treatment of active ankylosing spondylitis. The company stated that the study met all primary efficacy endpoints, including the Assessment of SpondyloArthritis International Society 20 (ASAS20) response, as well as key secondary endpoints such as ASAS40. The investigational biologic demonstrated significant improvements in disease activity, physical function, and quality of life for patients, positioning it as a potential new therapeutic option in the company's growing immunology portfolio.
• In January 2025, MoonLake Immunotherapeutics announced the initiation of patient screening for the S-OLARIS global Phase 2 clinical trial evaluating sonelokimab in patients with active axial spondyloarthritis, including ankylosing spondylitis. This trial was designed to assess the efficacy of the company’s investigational Nanobody® therapy, which inhibits both IL-17A and IL-17F, in reducing inflammation in the spine and sacroiliac joints. The company noted that the study would utilize advanced imaging techniques, including positron emission tomography (PET) combined with magnetic resonance imaging (MRI), to measure treatment response and gain deeper insights into the drug's impact on disease activity.
• In September 2024, UCB announced that the U.S. Food and Drug Administration (FDA) had approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with active ankylosing spondylitis (AS) and active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. This regulatory milestone made bimekizumab the first and only treatment approved for these conditions that selectively inhibits both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes. The approval was supported by data from Phase 3 clinical trials which demonstrated that the therapeutic provided consistent and sustained responses across the full spectrum of axial spondyloarthritis.
• In April 2024, the Russian biotechnology company Biocad announced that the Ministry of Health of the Russian Federation had registered Seniprutug, a first-in-class drug for the treatment of active ankylosing spondylitis. Developed in collaboration with a leading national medical research university, the drug utilizes a novel mechanism of action that targets a specific segment of the TRBV9+ T cell receptor, aiming to eliminate the autoimmune clones responsible for the disease while preserving general immunity. The company highlighted that this registration marked a significant breakthrough, offering a targeted therapeutic approach that addresses the underlying cause of the disease rather than solely managing symptoms.

Key Market Players

• AbbVie Inc.
• Amgen Inc.
• F. Hoffmann‑La Roche Ltd.
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Novartis AG
• UCB S.A.
• Sanofi S.A.
• Eli Lilly and Company
• Bristol‑Myers Squibb Compan

By Drug	By End Use	By Region
Cosentyx Humira Simponi Remicade Enbrel Cimzia	Hospitals Clinics Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Ankylosing Spondylitis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Ankylosing Spondylitis Therapeutics Market, By Drug:

• Cosentyx
• Humira
• Simponi
• Remicade
• Enbrel
• Cimzia

• Ankylosing Spondylitis Therapeutics Market, By End Use:

• Hospitals
• Clinics
• Others

• Ankylosing Spondylitis Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE